Name: Recombinant Human Tyrosine-protein kinase JAK1 (Jak1), partial
Brand: CUSABIO
SKU: CSB-EP011930HU

Product Details

Purity

Greater than 90% as determined by SDS-PAGE.

Target Names

JAK1

Uniprot No.

P23458

Research Area

Cancer

Alternative Names

JAK 1; JAK 1A; JAK 1B; JAK-1; JAK1; JAK1_HUMAN; JAK1A; JAK1B; Janus kinase 1 (a protein tyrosine kinase); Janus kinase 1; JTK3; Tyrosine protein kinase JAK 1; Tyrosine protein kinase JAK1; Tyrosine-protein kinase JAK1

Species

Homo sapiens (Human)

Source

E.coli

Expression Region

850-1154aa

Target Protein Sequence

EQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.

Mol. Weight

38.9kDa

Protein Length

Partial

Tag Info

N-terminal 6xHis-tagged

Form

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

The recombinant human Tyrosine-protein kinase JAK1 protein production starts with the co-cloning of the target gene (850-1154aa of JAK1) with the N-terminal 6xHis-tag gene into a vector that would be inserted into E.coli cells, followed by upstream bioprocessing, and subsequently the downstream process to purify and formulate into end products. The recombinant human JAK1 protein is collected and purified from the cell lysate through affinity chromatography. Its purity is greater than 90% as assessed by SDS-PAGE.

JAK1 is known to phosphorylate STAT proteins in response to various stimuli, leading to their nuclear translocation and subsequent gene expression regulation [4][5]. It is essential for activating STAT proteins in mammary glands and is particularly involved in epithelial compartment remodeling during post-lactational involution [1].

JAK1 has been implicated in cancer progression and promotes cellular processes such as cell proliferation, cell movement, and gene expression modulation [2][3]. Studies have shown that JAK1 interacts with various molecules such as miR-134-5p, STAT proteins, and interferon-inducible genes, to regulate cancer progression and immune responses [2][3][6]. Furthermore, JAK1 is linked to immune evasion in renal cell carcinoma, where it is stabilized by EHBP1L1 to promote IFN-γ/JAK1/STAT1 signaling and downstream PD-L1 expression [7].

References:
[1] K. Sakamoto, B. Wehde, K. Yoo, T. Kim, N. Rajbhandari, H. Shinet al., Janus kinase 1 is essential for inflammatory cytokine signaling and mammary gland remodeling, Molecular and Cellular Biology, vol. 36, no. 11, p. 1673-1690, 2016. https://doi.org/10.1128/mcb.00999-15
[2] B. Wehde, P. Rädler, H. Shrestha, S. Johnson, A. Triplett, & K. Wagner, Janus kinase 1 plays a critical role in mammary cancer progression, Cell Reports, vol. 25, no. 8, p. 2192-2207.e5, 2018. https://doi.org/10.1016/j.celrep.2018.10.063
[3] Y. He, H. Ma, J. Wang, Y. Kang, & Q. Xue, Mir‑20a‑5p inhibits endometrial cancer progression by targeting janus kinase 1, Oncology Letters, vol. 21, no. 5, 2021. https://doi.org/10.3892/ol.2021.12688
[4] W. Xiao, S. Ramanujam, D. Lindner, R. Kudaravalli, R. Freund, & D. Kalvakolanu, The polyoma virus t antigen interferes with interferon-inducible gene expression, Proceedings of the National Academy of Sciences, vol. 95, no. 3, p. 1085-1090, 1998. https://doi.org/10.1073/pnas.95.3.1085
[5] Y. Pan, G. Shu, L. Fu, K. Huang, X. Zhou, C. Guiet al., Ehbp1l1 drives immune evasion in renal cell carcinoma through binding and stabilizing jak1, Advanced Science, vol. 10, no. 11, 2023. https://doi.org/10.1002/advs.202206792
[6] X. Huang, Y. Chen, X. Zhang, L. Feimeng, & H. Ye, Extract of stellera chamaejasme l. inhibits the progression of hepatocellular carcinoma by regulating mir-134-5p and jak1/stat3 pathway, Cancer Biotherapy & Radiopharmaceuticals, vol. 35, no. 8, p. 586-595, 2020. https://doi.org/10.1089/cbr.2019.3229
[7] Y. Lee, S. Hyung, H. Jung, H. Kim, J. Staerk, S. Constantinescuet al., The ubiquitin-mediated degradation of jak1 modulates osteoclastogenesis by limiting interferon-β–induced inhibitory signaling, Blood, vol. 111, no. 2, p. 885-893, 2008. https://doi.org/10.1182/blood-2007-03-082941

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

■ Q&A

I am interested in several of your recombinant proteins. Can you please provide some informations:
For CSB-EP011930HU (all expression systems):
a.Sequence
b.Tag type
c.Tag position
d.Sizes and formats
e.Is the protein provided soluble in solution?
f.Is the protein purified from bacterial inclusion bodies are you supplied refolded or still in urea?
g.I want to use this protein for conjugation purposes and need it supplied in an amine free buffer (so not Tris). Can you supply this protein in one of the buffers at my request: phosphate, carbonate, or borate? Would there be an extra charge?

Thanks for your inquiry. Proteins will be supplied soluble in solution.
It is not certain for the protein to be expressed in the supernatant or precipitation, but our proteins are provided with folding correctly.
If you need it supplied in an amine free buffer (so not Tris). We can do this. Please mention this requirement in your official order. We can try to provide PBS buffer, this is not extra charged.
Recombinant Human Tyrosine-protein kinase JAK1(Jak1), partial
CSB-YP011930HU
CSB-EP011930HU
CSB-BP011930HU
CSB-MP011930HU
Expression Region:850-1154aa，C-terminal fragment, contains Protein kinase 2 domain
Tag information:EP,YP:N-terminal 6xHis-tagged;BP,MP:Tag type will be determined during the manufacturing process.
The expected tag for other expression systems are listed as follows:BP,MP:N-terminal 6xHis-tagged
Sequence:
You can view the full sequence on this page.

Target Background

Function

Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor. Directly phosphorylates STAT but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors.

Gene References into Functions

Low-dose radiation decreases tumor progression via the inhibition of the JAK1/STAT3 signaling axis in breast cancer cell lines and in a mouse xenograft model. PMID: 28240233
Case Report: breast implant-associated anaplastic large cell lymphoma with dual JAK1/STAT3 mutations. PMID: 29637270
A small drug acting as a JAK1/2 inhibitor may also counteract the repressing effects of IL-6. PMID: 29162613
These findings clarify JAK1 signalling mechanisms and demonstrate a critical function of JAK1 in protection against mycobacterial infection and possibly the immunological surveillance of cancer. PMID: 28008925
In the Title. PMID: 27554814
Study concluded that JAK1 plays a role in the pathogenesis of both vitiligo and psoriasis based on its upregulated level before treatment and downregulated level after treatment. PMID: 29127481
High JAK1 expression is associated with metastasis of pancreatic ductal adenocarcinoma. PMID: 28677798
IL6 family cytokine oncostatin-M (OSM) induced a switch to the EMT phenotype and protected cells from targeted drug-induced apoptosis in OSM receptors (OSMRs)/JAK1/STAT3-dependent manner PMID: 28729401
Amorfrutin A also inhibited activation of the upstream kinases Janus-activated kinase 1 (JAK1), JAK2 and Src signaling pathways. PMID: 28879797
Jak1 is required for the survival of anaplastic large cell lymphoma.Jak1 mutations in anaplastic large cell lymphoma. PMID: 28356514
The good consonance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the reasonable modification of molecules in order to design more efficient JAK 1 inhibitors. The developed models are expected to provide some directives for further synthesis of highly effective JAK 1 inhibitors. PMID: 28537140
Here we report a molecular mechanism by which JAK1 contributes to the malignant phenotype of activated B-cell diffuse large B-cell lymphoma (ABC DLBCL). Epigenetic regulation by JAK1 plays a prominent role in the gene expression program of ABC DLBCL cells by phosphorylating chromatin on H3Y41. The chromatin of nearly 3,000 genes had JAK1-dependent H3Y41 phosphorylation marks and required JAK1 for their expression. PMID: 27799566
miR-30e has a critical role in the suppression of hepatocellular carcinoma (HCC) and presents a novel mechanism of miRNA-mediated JAK1 expression in cancer cells that might be a good prognostic marker for survival of HCC patients. PMID: 28560434
We demonstrate that impaired recruitment of CD11b(+) myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model. PMID: 28039266
Whole-exome sequencing on patients with acute lymphoblastic leukemia (ALL) and discovered a somatic JAK1 S646P mutation. Functional studies demonstrated that only JAK1 S646P mutation could activate multiple signaling pathways, drive cytokine-independent cell growth, and promote proliferation of malignant cells in nude mice. PMID: 28410228
we have identified acquired activating mutations in JAK1 and STAT3 in two cases of effusion-limited BIA-ALCL and identified a possible contribution to disease development from a germline JAK3 variant. PMID: 27198716
JAK1 mutations are highly frequent in microsatellite unstable endometrial cancer, not associated with survival, but are associated with impaired upregulation of LMP7 and HLA class I and may therefore facilitate immune escape PMID: 27213585
We found that a significant higher gastric cancer risk was associated with IL-6 rs2069837G variant genotypes and JAK1 rs2230587A variant genotypes PMID: 27049718
6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiated the inhibitory effect of IFN-alpha on hepatocellular carcinoma cell proliferation through activation of the JAK/STAT signaling pathway by inhibiting SOCS3 expression. PMID: 29031523
JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability PMID: 29121062
Study provides evidence that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. PMID: 27903500
This study demonstrates that the nuclear import of JAK1 is essential for the optimal fitness of ABC DLBCL cells. PMID: 28031410
JAK1 rs11576173 and rs1497056 genotypes were significantly related to severe necroinflammatory activity (NIA) grade of chronic hepatitis C patients. PMID: 28704535
Multiple myeloma cells over express JAK1/2 and suggest combined chemotherapy with ruxolitinib, bortezomib and lenalidomide to inhibit JAK/STAT pathway. PMID: 28645562
Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFNgamma recepter, resulting in an inhibition of STAT1 phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC specimens is negatively correlated with the levels of IFIT2 and pSTAT1 PMID: 27893714
Multilevel genomic analyses of microsatellite instability+ colorectal cancer revealed molecular heterogeneity with clinical relevance, including tumor immunogenicity and a favorable patient outcome associated with JAK1 mutations and the transcriptomic subgroup CMS1 PMID: 28539123
a causal relationship between MLH1-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported. PMID: 27436342
Data show that moringin (GMG-ITC) had a limited inhibitory effect on IFNalpha-induced STAT1 and STAT2 activity, indicating differentially targeting JAK/STAT signaling pathways. PMID: 27304884
our studies highlight Jak1 as the first identified substrate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT3 inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 overexpression PMID: 27440725
In this structure, the receptor peptide forms an 85-A-long extended chain, in which both the previously identified box1 and box2 regions bind simultaneously to the FERM and SH2-like domains of JAK1. PMID: 27725180
Results reveal the structure of box1 from class II cytokine receptors IFNLR1 and IL10RA bound to the FERM-SH2 domain of human JAK1, identifying a consensus motif for JAK1 interaction. PMID: 27133025
study demonstrated that miR-9 could inhibit activation of the NLRP3 inflammasome and attenuate atherosclerosis-related inflammation, likely through the JAK1/STAT1 signaling pathway. Therefore, miR-9 may serve as a potential therapeutic target for atherosclerosis. PMID: 28334721
miR-340 suppressed HCC cell proliferation and invasion by regulating the JAK1/STAT3 pathway PMID: 27998770
this study identifies a psoriasis-protective JAK1 haplotype in the Korean population PMID: 27774581
Data show that tight junction protein 1 (TJP1) suppressed expression of the catalytically proteasome subunits LMP7 and LMP2, decreased proteasome activity, and enhanced proteasome inhibitor sensitivity in vitro and in vivo through suppression of EGFR/JAK1/STAT3 signaling. PMID: 27132469
EGFR Del 19 may promote Fn14 and JAK1/STAT1 expression in NSCLC. PMID: 27350337
Piperlongumine reduced the phosphorylation of Janus kinase (JAK)1, JAK2 and signal transducer and activator of transcription (STAT)3 in a concentrationdependent manner PMID: 27053336
JAK1 rs310241 C-related genotype and allele are involved in AR susceptibility, making them potentially useful genetic biomarkers for allergic rhinitis susceptibility in the Chinese Han population. PMID: 27007833
Data show that astaxanthin functions as a potent inhibitor of A549 lung cancer cell growth by targeting Janus kinase 1 a(JAK1)/STAT3 transcription factor (STAT3) signaling pathway. PMID: 27371847
Genetic Variation in the JAK1 gene is associated with distal Colonic Disease, Stricturing Disease Behavior. PMID: 26937622
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. PMID: 26701727
Foot-and-mouth disease virus VP3 interacted with JAK1/2, degraded JAK1, and inhibited the tyrosine phosphorylation, dimerization and nuclear accumulation of STAT1. PMID: 26901336
Data suggest that targeting both TGF-beta and Janus kinase 1 (JAK1) signaling could be explored therapeutically in pancreatic ductal adenocarcinomas (PDACs) patients whose cancers exhibit an angiogenesis gene signature. PMID: 26586478
When association tests were applied to data from the Diabetes Heart Study, it found exome variants of POMGNT1 and JAK1 genes were associated with type 2 diabetes. PMID: 26783077
Studies indicate that Janus kinase 1 (JAK1) inhibition leads to depression in inflammatory cytokine expression associated with MF-related constitutional symptoms. PMID: 25586607
Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. PMID: 26188635
Increased expression of SgK223 occurs in PDAC, and overexpression of SgK223 in pancreatic ductal epithelial cells promotes acquisition of a migratory and invasive phenotype through enhanced JAK1/Stat3 signaling PMID: 26215634
Data show that IFN-lambda induced a faster but shorter expression of suppressor of cytokine signaling 1 (SOCS1) which inhibited Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway and phosphorylation. PMID: 26193702
Shp-2 contributes to the control of respiratory syncytial virus replication and progeny production in pulmonary alveolar epithelial cells by interfering with IFN-alpha-induced Jak/Stat1 pathway activation PMID: 26119280
Data show that JAK/STAT signaling inhibition is potentiated by Bcl-xL (B-cell lymphoma-extra large) blockade in interleukin 2 (IL-2) dependent adult T-cell leukemia cells. PMID: 26396258

Hide All

Subcellular Location

Endomembrane system; Peripheral membrane protein. Note=Wholly intracellular, possibly membrane associated.

Protein Families

Protein kinase superfamily, Tyr protein kinase family, JAK subfamily

Tissue Specificity

Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.

Database Links

HGNC: 6190

OMIM: 147795

KEGG: hsa:3716

STRING: 9606.ENSP00000343204

UniGene: Hs.207538

Place an order now

I. Product details

Product name *

Code *

Size *

Quantity *

Message

II. Contact details

Name *

Email address *

Company/Organization

Phone

III. Ship To

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

IV. Bill To Same as Shipping Address